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Background Background Substantial weight gain is
Substantial weight gain is common with many atypical common with many atypical antipsychotics. antipsychotics.
Aims Aims To evaluate the extent, time
To evaluate the extent, time course and predictors of weight gain and course and predictors of weight gain and its effect on study retention among people its effect on study retention among people with first-episode psychosis treated with with first-episode psychosis treated with olanzapine or haloperidol. olanzapine or haloperidol.
Method Method Survival analysis assessed time
Survival analysis assessed time to potentially clinically significant weight to potentially clinically significant weight gain ( gain (5 57%) and the effect of weight gain 7%) and the effect of weight gain on study retention.Weight gain during the on study retention.Weight gain during the 2-year study was summarised using last-2-year study was summarised using lastobservation-carried-forward (LOCF), observation-carried-forward (LOCF), observed cases and study completion observed cases and study completion approaches. approaches. 2) for haloperidol.Change in body mass index was significantly body mass index was significantly predicted only by treatment group predicted only by treatment group ( (P P5 50.0001). 0.0001).
Results

Conclusions Conclusions Olanzapine was
Olanzapine was associated with significantly greater associated with significantly greater weight gain than haloperidol, with both weight gain than haloperidol, with both leading to greater weight gain than leading to greater weight gain than previously described. previously described.
Declaration of interest Declaration of interest This work
This work was financially supported by The introduction of atypical antipsyThe introduction of atypical antipsychotics has substantially changed the chotics has substantially changed the treatment of schizophrenia. Although treatment of schizophrenia. Although atypical antipsychotics have dramatically atypical antipsychotics have dramatically reduced the frequency of acute extrapyrareduced the frequency of acute extrapyramidal symptoms, substantial weight gain midal symptoms, substantial weight gain is common with many of these medicais common with many of these medications (Allison tions (Allison et al et al, 1999) . Estimates of , 1999) . Estimates of mean weight gain associated with atypical mean weight gain associated with atypical antipsychotics have varied greatly and are antipsychotics have varied greatly and are confounded by the extent of previous confounded by the extent of previous antipsychotic treatment (Ganguli antipsychotic treatment (Ganguli et al et al, , 2001 ) and the statistical methodology 2001) and the statistical methodology used to estimate weight gain from clinical used to estimate weight gain from clinical trials with a significant withdrawal rate trials with a significant withdrawal rate (Allison & Casey, 2001) . Typically, such (Allison & Casey, 2001) . Typically, such trials estimate weight gain on an intenttrials estimate weight gain on an intentto-treat basis using the last-observationto-treat basis using the last-observationcarried-forward (LOCF) approach. Esticarried-forward (LOCF) approach. Estimating weight gain from observed cases mating weight gain from observed cases and study completers provides compleand study completers provides complementary perspectives. In this study, we mentary perspectives. In this study, we investigated the extent and time course investigated the extent and time course of olanzapine-and haloperidol-associated of olanzapine-and haloperidol-associated weight gain in the treatment of firstweight gain in the treatment of firstepisode psychosis, the clinical correlates episode psychosis, the clinical correlates of weight gain and the association of of weight gain and the association of weight gain with treatment response and weight gain with treatment response and adherence. adherence.
METHOD METHOD
This analysis was based on the data This analysis was based on the data collected as part of a multicentre randomcollected as part of a multicentre randomised double-blind clinical trial. The design ised double-blind clinical trial. 
Participants Participants
Study participants met DSM-IV criteria Study participants met DSM-IV criteria for schizophrenia, schizophreniform disfor schizophrenia, schizophreniform disorder or schizoaffective disorder (American order or schizoaffective disorder (American Psychiatric Association, 1994) and were Psychiatric Association, 1994) and were between 16 and 40 years of age. All had exbetween 16 and 40 years of age. All had experienced psychotic symptoms for at least 1 perienced psychotic symptoms for at least 1 month but no more than 60 months, met month but no more than 60 months, met predefined criteria for being at least moderpredefined criteria for being at least moderately ill, and were determined to be in clinately ill, and were determined to be in clinical need of an antipsychotic medication. ical need of an antipsychotic medication. All participants or their authorised legal All participants or their authorised legal representative provided written informed representative provided written informed consent for this study after the procedures consent for this study after the procedures had been fully explained. The appropriate had been fully explained. The appropriate institutional review boards approved the institutional review boards approved the study. study.
Individuals were excluded from particiIndividuals were excluded from participating if they met any of the study exclupating if they met any of the study exclusion criteria (Lieberman sion criteria (Lieberman et al et al, 2003) . They , 2003) . They were excluded if they had received prior were excluded if they had received prior antipsychotic treatment for more than 16 antipsychotic treatment for more than 16 cumulative weeks, had ever received clozacumulative weeks, had ever received clozapine, or were currently in need of treatment pine, or were currently in need of treatment with anticonvulsants, antidepressants, with anticonvulsants, antidepressants, benzodiazepines (except for treatment of benzodiazepines (except for treatment of agitation and extrapyramidal symptoms), agitation and extrapyramidal symptoms), or other psychotropic medications. or other psychotropic medications.
Study design and procedures Study design and procedures
Participants were randomly assigned to Participants were randomly assigned to olanzapine or haloperidol under doubleolanzapine or haloperidol under doubleblind conditions. In the first 6 weeks of the blind conditions. In the first 6 weeks of the study, doses could be titrated in the range study, doses could be titrated in the range of 5-10 mg/day (olanzapine) and 2-6 mg/ of 5-10 mg/day (olanzapine) and 2-6 mg/ day (haloperidol); for the second 6 weeks day (haloperidol); for the second 6 weeks of the study, doses could be further of the study, doses could be further adjusted in the range of 5-20 mg/day (olanadjusted in the range of 5-20 mg/day (olanzapine) and 2-20 mg/day (haloperidol). zapine) and 2-20 mg/day (haloperidol). Antidepressants and mood stabilisers could Antidepressants and mood stabilisers could not be used during the first 12 weeks of the not be used during the first 12 weeks of the study. Following the 12-week acute treatstudy. Following the 12-week acute treatment period, fluoxetine 10-60 mg/day ment period, fluoxetine 10-60 mg/day could be prescribed for individuals meeting could be prescribed for individuals meeting DSM-IV criteria for major depressive dis-DSM-IV criteria for major depressive disorder. Lithium carbonate or valproate order. Lithium carbonate or valproate could be added if they failed to respond to could be added if they failed to respond to fluoxetine or if they developed mania or a fluoxetine or if they developed mania or a mixed affective state. mixed affective state.
Psychopathology was assessed using Psychopathology was assessed using the Positive and Negative Syndrome Scale the Positive and Negative Syndrome Scale (PANSS; Kay (PANSS; Kay et al et al, 1992) as the primary , 1992) as the primary efficacy variable. The PANSS was adminisefficacy variable. The PANSS was administered at study entry, on the day of tered at study entry, on the day of randomisation, weekly for the first 6 weeks, randomisation, weekly for the first 6 weeks, every 2 weeks for the next 6 weeks and then every 2 weeks for the next 6 weeks and then monthly for the remainder of the study. monthly for the remainder of the study. Body weight was measured at each of these Body weight was measured at each of these visits. Non-fasting serum glucose and visits. Non-fasting serum glucose and cholesterol levels were measured on the cholesterol levels were measured on the day of study entry, on the day of randomisday of study entry, on the day of randomisation, at 12 weeks, 6 months, 12 months, ation, at 12 weeks, 6 months, 12 months, 18 months and 24 months. 18 months and 24 months. Course and predictors of weight gain in people Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine with first-episode psychosis treated with olanzapine or haloperidol or haloperidol
Statistical analyses Statistical analyses
We identified the primary outcome to test We identified the primary outcome to test treatment group differences as the event of treatment group differences as the event of 'clinically significant weight gain', defined 'clinically significant weight gain', defined as as 5 57% increase in weight (kg) from 7% increase in weight (kg) from baseline; this definition is consistent with baseline; this definition is consistent with the US Food and Drug Administration the US Food and Drug Administration guidelines (Sachs & Guille, 1999) . The guidelines (Sachs & Guille, 1999 ). The primary analysis was able to use the primary analysis was able to use the intent-to-treat population of all randomised intent-to-treat population of all randomised participants and compared the Kaplanparticipants and compared the KaplanMeier survival curves of the two treatments Meier survival curves of the two treatments using the log-rank test. A Cox regression using the log-rank test. A Cox regression elaborated the findings by modelling the elaborated the findings by modelling the treatment effects jointly with other potentreatment effects jointly with other potentially important covariates selected from tially important covariates selected from baseline body mass index (BMI), age, genbaseline body mass index (BMI), age, gender, ethnicity, smoking status, premorbid der, ethnicity, smoking status, premorbid functioning, diagnosis, age at onset, durafunctioning, diagnosis, age at onset, duration of untreated illness and history of pretion of untreated illness and history of previous antipsychotic treatment (backward vious antipsychotic treatment (backward model selection, model selection, P P5 50.05 to stay). 0.05 to stay). The descriptive statistics for amount of The descriptive statistics for amount of weight gained were plotted using data for weight gained were plotted using data for LOCF, observed cases and completers to LOCF, observed cases and completers to examine the effect of early withdrawal on examine the effect of early withdrawal on weight gain estimates. A more sophisticated weight gain estimates. A more sophisticated approach was taken to model growth approach was taken to model growth curves of BMI change in the first 12 weeks curves of BMI change in the first 12 weeks using a random coefficient mixed model, using a random coefficient mixed model, and to identify significant clinical predicand to identify significant clinical predictors (as described above) for the course of tors (as described above) for the course of BMI change. The correlation of weight gain BMI change. The correlation of weight gain and clinical outcome (as assessed by PANSS and clinical outcome (as assessed by PANSS total score) was calculated at each time total score) was calculated at each time point and summarised using mixed models point and summarised using mixed models with repeated measures. A hierarchy of with repeated measures. A hierarchy of Cox regression models was carried out to Cox regression models was carried out to assess the difference in study retention assess the difference in study retention between the two treatment groups, as between the two treatment groups, as well as the contribution of symptom well as the contribution of symptom improvement and weight gain to withimprovement and weight gain to withdrawal from the study. Only the primary drawal from the study. Only the primary analysis on treatment effect was tested at analysis on treatment effect was tested at a two-sided a two-sided a a level of 0.05. The supplemenlevel of 0.05. The supplemental exploratory analysis was undertaken tal exploratory analysis was undertaken to expand our understanding of clinical to expand our understanding of clinical aspects of weight gain, and no adjustment aspects of weight gain, and no adjustment for multiple comparisons was considered for multiple comparisons was considered necessary. The statistical analysis was necessary. The statistical analysis was performed using SAS version 8.01 for performed using SAS version 8.01 for Windows (SAS Institute, Cary, North Windows (SAS Institute, Cary, North Carolina, USA). Carolina, USA).
RESULTS RESULTS
In total, 263 individuals entered the study In total, 263 individuals entered the study (olanzapine, (olanzapine, n n¼131; haloperidol, 131; haloperidol, n n¼132). 132). (Figure 1 illustrates the progress of ( Figure 1 illustrates the progress of participants through the trial.) Table 1 participants through the trial.) Table 1 summarises baseline demographic and clinsummarises baseline demographic and clinical features of the sample. The acute-phase ical features of the sample. The acute-phase mean modal doses were 9.1 mg/day of olanmean modal doses were 9.1 mg/day of olanzapine and 4.4 mg/day of haloperidol. zapine and 4.4 mg/day of haloperidol.
Time to clinically significant Time to clinically significant weight gain weight gain Among olanzapine-treated participants, 95 Among olanzapine-treated participants, 95 met the clinically significant weight gain met the clinically significant weight gain criterion by the end of the 2-year study; criterion by the end of the 2-year study; one individual remaining on treatment and one individual remaining on treatment and 35 who had discontinued treatment did not 35 who had discontinued treatment did not meet this criterion. Among haloperidolmeet this criterion. Among haloperidoltreated participants, the numbers were 51, treated participants, the numbers were 51, 3 and 78, respectively. Figure 2 shows the 3 and 78, respectively. Figure 2 shows the percentage of participants who were expercentage of participants who were expected to have clinically significant weight pected to have clinically significant weight gain at each time point, adjusting for withgain at each time point, adjusting for withdrawal rates as calculated by drawal rates as calculated by Kaplan-Meier Kaplan-Meier estimates. Olanzapineestimates. Olanzapine-treated participants treated participants met the clinically significant weight gain met the clinically significant weight gain criterion at a significantly faster rate than criterion at a significantly faster rate than haloperidol-treated individuals ( haloperidol-treated individuals (w w 2 2 (1) (1)¼67.9, 67.9, P P5 50.0001; log-rank test). The median 0.0001; log-rank test). The median CONSORT diagram with number of participants in trial or discontinued at12 weeks,1year and 2 years. treatment time before meeting the clinically treatment time before meeting the clinically significant weight gain criterion was 5 significant weight gain criterion was 5 weeks for the olanzapine-treated group weeks for the olanzapine-treated group (95% CI 4-6) and 28 weeks (95% CI 16-(95% CI 4-6) and 28 weeks (95% CI 16-40) for the haloperidol-treated group. 40) for the haloperidol-treated group. Results from the Cox regression model Results from the Cox regression model confirmed the treatment-group differences confirmed the treatment-group differences in the likelihood of developing clinically in the likelihood of developing clinically significant weight gain. The hazard significant weight gain. The hazard was more than five times greater for was more than five times greater for olanzapine-treated participants than for olanzapine-treated participants than for those treated with haloperidol (hazard those treated with haloperidol (hazard ratio ratio¼5.19, 5.19, w w 2 2 (1) (1)¼66.3, 66.3, P P5 50.0001). Par-0.0001). Participants with higher baseline weight took ticipants with higher baseline weight took longer to gain longer to gain 5 57% of their baseline body 7% of their baseline body weight, representing a 12% reduction in weight, representing a 12% reduction in hazard ( hazard (w w 2 2 (1) (1)¼20.9, 20.9, P P5 50.0001). In addi-0.0001). In addition, Black participants and those from tion, Black participants and those from minority ethnic groups demonstrated a minority ethnic groups demonstrated a significantly faster rate of clinically sigsignificantly faster rate of clinically significant weight gain (hazard ratio nificant weight gain (hazard ratio¼1.58, 1.58, w w 2 2 (1) (1)¼6.28, 6.28, P P¼0.01). The effects of base-0.01). The effects of baseline weight and ethnicity on the likelihood line weight and ethnicity on the likelihood of developing clinically significant weight of developing clinically significant weight gain were not related to treatment group, gain were not related to treatment group, as indicated by the non-significant interacas indicated by the non-significant interactions between these variables and treatment tions between these variables and treatment group ( group (P P4 40.23). 0.23).
Descriptive statistics Descriptive statistics for the time course of weight gain for the time course of weight gain Figure 3a presents mean changes in weight Figure 3a presents mean changes in weight assessed by LOCF analysis. Individuals in assessed by LOCF analysis. Individuals in both treatment groups gained weight both treatment groups gained weight rapidly in the first 12 weeks of treatment. rapidly in the first 12 weeks of treatment. The pace of weight gain tapered gradually The pace of weight gain tapered gradually thereafter and stabilised after 1 year. In thereafter and stabilised after 1 year. In the olanzapine-treated group, the mean the olanzapine-treated group, the mean weight gain estimated using LOCF was weight gain estimated using LOCF was 7.3 kg (s. Figure 3b shows mean changes in Figure 3b shows mean changes in weight assessed among observed-cases. weight assessed among observed-cases. Compared with the LOCF plots, the Compared with the LOCF plots, the observed-cases plots show a longer course observed-cases plots show a longer course of steady weight gain: up to 36 weeks in of steady weight gain: up to 36 weeks in the haloperidol group and 60 weeks in the the haloperidol group and 60 weeks in the olanzapine group. The overall weight gain olanzapine group. The overall weight gain was also greater when assessed using the was also greater when assessed using the observed-cases data. In the olanzapineobserved-cases data. In the olanzapinetreated group, the observed mean weight treated group, the observed mean weight gain was 9.2 kg (s. Figure 3c shows the time course for Figure 3c shows the time course for weight gain among olanzapine-and weight gain among olanzapine-and haloperidol-treated participants who haloperidol-treated participants who completed 12 weeks, 1 year and 2 years completed 12 weeks, 1 year and 2 years of treatment. The time course for weight of treatment. The time course for weight gain for the three completer groups is gain for the three completer groups is remarkably similar and is similar to the remarkably similar and is similar to the results of the observed-cases analysis. results of the observed-cases analysis.
The BMI change during the study folThe BMI change during the study follows a pattern similar to that for weight gain lows a pattern similar to that for weight gain (kg) when analysed using LOCF, observed (kg) when analysed using LOCF, observed cases and completers. Last-observationcases and completers. Last-observationcarried-forward analysis showed that in carried-forward analysis showed that in the olanzapine group the mean BMI the olanzapine group the mean BMI increased from 23. Overall, the time course of weight gain Overall, the time course of weight gain from baseline could be best described as from baseline could be best described as an increasing binomial curve, whose rate an increasing binomial curve, whose rate of increase stabilised gradually over time. of increase stabilised gradually over time. Body mass index change was not preBody mass index change was not predicted by age, gender, smoking status, dicted by age, gender, smoking status, diagnosis, premorbid functioning, age at diagnosis, premorbid functioning, age at onset, duration of illness or history of preonset, duration of illness or history of previous antipsychotic treatment. Individuals vious antipsychotic treatment. Individuals with higher pre-treatment BMI had larger with higher pre-treatment BMI had larger BMI increases in the first week of treat-BMI increases in the first week of treatment but followed the same rate of weight ment but followed the same rate of weight gain as the others thereafter. Olanzapinegain as the others thereafter. Olanzapinetreated participants gained weight signifitreated participants gained weight significantly faster than haloperidol-treated cantly faster than haloperidol-treated individuals but seemed to have greater individuals but seemed to have greater propensity to stabilise over time, as indipropensity to stabilise over time, as indicated by both the significantly larger cated by both the significantly larger positive linear slope and larger negative positive linear slope and larger negative quadratic slope in the growth curve quadratic slope in the growth curve models on BMI. The model-estimated models on BMI. The model-estimated linear slopes were 0.14 BMI units/week linear slopes were 0.14 BMI units/week for haloperidol for haloperidol v v. . Black participants and 0.0001). Black participants and those from minority ethnic groups gained those from minority ethnic groups gained weight faster than White participants weight faster than White participants and maintained the high rate of weight and maintained the high rate of weight gain longer. The effects of baseline BMI gain longer. The effects of baseline BMI and ethnicity on the BMI increase rate and ethnicity on the BMI increase rate did not differ significantly between the did not differ significantly between the olanzapine-and haloperidol-treated groups olanzapine-and haloperidol-treated groups ( (P P4 40.40). 0.40).
Laboratory correlates Laboratory correlates of weight gain of weight gain
Body mass index changes did not signifiBody mass index changes did not significantly correlate with changes in non-fasting cantly correlate with changes in non-fasting 5 3 9 5 3 9 AUTHOR'S PROOF AUTHOR'S PROOF Fig. 2 Kaplan^Meier estimates for probability of clinically significant weight gain for participants who have Kaplan^Meier estimates for probability of clinically significant weight gain for participants who have received antipsychotic treatment for a certain period (olanzapine, received antipsychotic treatment for a certain period (olanzapine, n n¼131; haloperidol, 131; haloperidol, n n¼132). 
Weight gain and clinical response Weight gain and clinical response
Overall, we found evidence that higher Overall, we found evidence that higher weight gain was associated with greater weight gain was associated with greater symptom improvement before week 12, symptom improvement before week 12, but the association was diminished therebut the association was diminished thereafter. At weeks 1 and 6, a modest correlaafter. At weeks 1 and 6, a modest correlation was observed ( tion was observed (r r¼0.21, 0.21, P P¼0.02) 0.02) between weight gain and clinical improvebetween weight gain and clinical improvement in both treatment groups; after ment in both treatment groups; after 12 weeks, this association could no longer 12 weeks, this association could no longer be detected. The mixed model with be detected. The mixed model with repeated measures confirmed this obserrepeated measures confirmed this observation. Changes in BMI were significantly vation. Changes in BMI were significantly associated with clinical improvement for associated with clinical improvement for 5 4 0 5 4 0 AUTHOR'S PROOF AUTHOR'S PROOF Mean weight change for modified intent-to-treat samples in olanzapine and haloperidol treatment groups. (a) Mean weight change (kg) among participants with at least one post-baseline weight measure included (two people in the haloperidol group had missing baseline weight; valid last-observation-carried-forward with at least one post-baseline weight measure included (two people in the haloperidol group had missing baseline weight; valid last-observation-carried-forward (LOCF ) (LOCF ) n n¼131for olanzapine). Missing values after the first follow-up were filled in using the LOCF approach. 131for olanzapine). Missing values after the first follow-up were filled in using the LOCF approach. ** ** ööö, Haloperidol; ööö, Haloperidol;~ööö , olanzapine. (b) Mean weight ööö , olanzapine. (b) Mean weight change (kg) among observed cases at each visit in olanzapine and haloperidol treatment groups.The patterns presented are from gradually decreasing sample sizes, owing change (kg) among observed cases at each visit in olanzapine and haloperidol treatment groups.The patterns presented are from gradually decreasing sample sizes, owing to early withdrawal. to early withdrawal. ** ** ööö, Haloperidol; ööö, Haloperidol;~ööö , olanzapine. (c) Mean weight change (kg) among the 12-week, 1-year and 2-year completers in olanzapine and halo-ööö , olanzapine. (c) Mean weight change (kg) among the 12-week, 1-year and 2-year completers in olanzapine and haloperidol treatment groups (at 12 weeks: olanzapine, peridol treatment groups (at 12 weeks: olanzapine, n n¼92; haloperidol, 92; haloperidol, n n¼79; at 1 year: olanzapine, 79; at 1 year: olanzapine, n n¼51; haloperidol, 51; haloperidol, n n¼39; at 2 years: olanzapine, 39; at 2 years: olanzapine, n n¼31; haloperidol, 31; haloperidol, n n¼16). 16). ** ** ööö, Haloperidol 12-week completers; ööö, Haloperidol 12-week completers; ** ** ööö ööö, haloperidol 1-year completers; , haloperidol 1-year completers; ** ** ööö, haloperidol 2-year completers; ööö, haloperidol 2-year completers;~ööö , olanzapine, 12-week ööö , olanzapine, 12-week completers; completers;~ööö ööö , olanzapine1year completers;
, olanzapine 1 year completers;~ööö , olanzapine 2-year completers. ööö , olanzapine 2-year completers.
both olanzapineand haloperidolboth olanzapineand haloperidoltreated participants ( treated participants (F F(1,3364) (1,3364)¼50.05, 50.05, P P5 50.001).
The association was 0.001).
The association was significantly reduced at later stages of significantly reduced at later stages of treatment ( treatment (F F(31,3364) (31,3364)¼2.12, 2.12, P P5 50.001). 0.001).
Weight gain and study retention Weight gain and study retention
In separate Cox regression models, olanzaIn separate Cox regression models, olanzapine treatment, higher BMI increase and pine treatment, higher BMI increase and greater symptom improvement each pregreater symptom improvement each predicted a significantly smaller hazard of dicted a significantly smaller hazard of early withdrawal from the study (see early withdrawal from the study (see models 1-3, Table 2 ). When modelled models 1-3, Table 2 ). When modelled jointly (see model 4, Table 2 ), reduction jointly (see model 4, Table 2 ), reduction in the PANSS total score remained the in the PANSS total score remained the most significant predictor of better study most significant predictor of better study retention. With every 10 points of PANSS retention. With every 10 points of PANSS improvement, the hazard rate of early improvement, the hazard rate of early study discontinuation was reduced by study discontinuation was reduced by 29%; even after controlling for weight gain 29%; even after controlling for weight gain and drug effect, the reduction remained at and drug effect, the reduction remained at 28%. Greater BMI increase also reduced 28%. Greater BMI increase also reduced the hazard ratio for study discontinuation the hazard ratio for study discontinuation by 11%, but the effect was reduced to by 11%, but the effect was reduced to 7% after the effects of drug and PANSS 7% after the effects of drug and PANSS improvement were taken into account. improvement were taken into account.
DISCUSSION DISCUSSION
Weight gain estimates Weight gain estimates
This study is unique in examining the This study is unique in examining the weight gain associated with antipsychotic weight gain associated with antipsychotic treatment in a large randomised doubletreatment in a large randomised doubleblind study of people with first-episode psyblind study of people with first-episode psychosis and very limited previous exposure chosis and very limited previous exposure to antipsychotic medication. Previous estito antipsychotic medication. Previous estimates of mean olanzapine-associated mates of mean olanzapine-associated weight gain have ranged from 2.2 kg over weight gain have ranged from 2.2 kg over 4 months to 10.0 kg over 7 months (Beasley 4 months to 10.0 kg over 7 months (Beasley et al et al, 1997; Tollefson , 1997; Tollefson et al et al, 1997; Allison , 1997; Allison et et al al, 1999; Gupta , 1999; Gupta et al et al, 1999; Sheitman , 1999; Sheitman et al et al, , 1999; Ganguli 1999; Ganguli et al et al, 2001; Kinon , 2001; Kinon et al et al, , 2001 ). Estimates of weight gain in this sam-2001). Estimates of weight gain in this sample varied greatly depending on the method ple varied greatly depending on the method used: LOCF resulted in lower estimates used: LOCF resulted in lower estimates of weight gain among both olanzapineof weight gain among both olanzapineand haloperidol-treated participants, and haloperidol-treated participants, whereas the analysis of observed cases and whereas the analysis of observed cases and completers yielded higher estimates. Applicompleters yielded higher estimates. Application of the observed-cases methodology cation of the observed-cases methodology has demonstrated that olanzapine was assohas demonstrated that olanzapine was associated with a mean 2-year weight gain of ciated with a mean 2-year weight gain of 15.4 kg, whereas haloperidol-associated 15.4 kg, whereas haloperidol-associated mean weight gain was 7.5 kg. These mean weight gain was 7.5 kg. These estimates are higher than previously reestimates are higher than previously reported for these two drugs and raise quesported for these two drugs and raise questions about what degree of weight gain tions about what degree of weight gain would be observed for other antipsychotics would be observed for other antipsychotics if they were examined using a similar study if they were examined using a similar study design and analysis methods (Allison design and analysis methods (Allison et al et al, , 1999) . 1999).
The magnitude of weight gain observed The magnitude of weight gain observed is of clinical concern; Table 3 uses criteria is of clinical concern; Table 3 uses criteria established by the US National Heart, established by the US National Heart, Lung, and Blood Institute to describe the Lung, and Blood Institute to describe the number and percentage of participants at number and percentage of participants at each time point of the study who would each time point of the study who would be categorised as of normal weight be categorised as of normal weight (BMI (BMI5 525), overweight (25 25 
Clinical predictors of weight gain Clinical predictors of weight gain
There has been much interest in the possThere has been much interest in the possibility that weight gain associated with ibility that weight gain associated with antipsychotics may be related to a range antipsychotics may be related to a range of clinical parameters (for review see of clinical parameters (for review see Blin & Micallef, 2001 ). To date, such Blin & Micallef, 2001 ). To date, such correlations have been mainly studied correlations have been mainly studied among people treated with clozapine. among people treated with clozapine. Clozapine-associated weight gain has been Clozapine-associated weight gain has been reported to be more likely in people who reported to be more likely in people who started treatment at a lower weight, in started treatment at a lower weight, in women, in younger people, in those treated women, in younger people, in those treated with higher doses of clozapine and in with higher doses of clozapine and in people receiving antipsychotic treatment people receiving antipsychotic treatment for the first time (Blin & Micallef, 2001) . for the first time (Blin & Micallef, 2001) .
In this study, we were unable to identify In this study, we were unable to identify predictors of the amount of weight gained predictors of the amount of weight gained other than treatment group. However, our other than treatment group. However, our data clearly demonstrate that virtually all data clearly demonstrate that virtually all of the participants treated with olanzapine of the participants treated with olanzapine and approximately three-quarters of those and approximately three-quarters of those treated with haloperidol were predicted to treated with haloperidol were predicted to gain gain 4 47% of their baseline body weight 7% of their baseline body weight after 1 year of treatment. after 1 year of treatment.
Metabolic correlates Metabolic correlates of weight gain of weight gain
Elevations in glucose levels have been Elevations in glucose levels have been described in people receiving some described in people receiving some atypical and some typical antipsychotics atypical and some typical antipsychotics (Wirshing, 2001; Newcomer (Wirshing, 2001; Newcomer et al et al, 2002; , 2002; Lindenmayer Lindenmayer et al et al, 2003) . Increases in cho-, 2003) . Increases in cholesterol and triglyceride levels have also lesterol and triglyceride levels have also been described in individuals receiving been described in individuals receiving clozapine and olanzapine (Wirshing, 2001; clozapine and olanzapine (Wirshing, 2001; Lindenmayer Lindenmayer et al et al, 2003) . In our study, , 2003). In our study, 5 4 1 5 4 1 AUTHOR'S PROOF AUTHOR'S PROOF Table 2  Table 2 Cox regression models for effects of weight gain and clinical improvement on study discontinuation Cox regression models for effects of weight gain and clinical improvement on study discontinuation weight change was not significantly correweight change was not significantly correlated with changes in non-fasting glucose lated with changes in non-fasting glucose levels, but was significantly correlated with levels, but was significantly correlated with increases in non-fasting cholesterol levels at increases in non-fasting cholesterol levels at some time points for both treatment some time points for both treatment groups. Given the extent of the weight gain groups. Given the extent of the weight gain in both treatment groups, it would clearly in both treatment groups, it would clearly be important to assess fasting glucose and be important to assess fasting glucose and complete lipid profiles in future clinical complete lipid profiles in future clinical trials of antipsychotic medications for trials of antipsychotic medications for first-episode psychosis to further evaluate first-episode psychosis to further evaluate the extent to which there is a significant the extent to which there is a significant correlation between weight gain and correlation between weight gain and changes in glucose and lipid levels. changes in glucose and lipid levels. (Blin & Micallef, 2001) . been inconsistent (Blin & Micallef, 2001 ).
We were able to demonstrate the prevWe were able to demonstrate the previously reported association between weight iously reported association between weight gain and clinical response. However, our gain and clinical response. However, our analysis found that this association was analysis found that this association was present only in the early weeks of treatment present only in the early weeks of treatment and that even at these points it was small, and that even at these points it was small, accounting for only 4% of the variance in accounting for only 4% of the variance in clinical improvement observed in both clinical improvement observed in both treatment groups at weeks 1 and 6. After treatment groups at weeks 1 and 6. After 12 weeks, weight gain did not account for 12 weeks, weight gain did not account for any variance in clinical improvement in any variance in clinical improvement in either treatment group. either treatment group. There are a number of possible explaThere are a number of possible explanations for this finding. Use of LOCF data nations for this finding. Use of LOCF data for studying this association is problematic for studying this association is problematic because participants who withdraw early because participants who withdraw early may experience both little clinical improvemay experience both little clinical improvement and little weight gain, whereas those ment and little weight gain, whereas those who remain in the study for longer periods who remain in the study for longer periods are expected to have both greater clinical are expected to have both greater clinical improvement and higher weight gain. Use improvement and higher weight gain. Use of LOCF data may therefore lead to a of LOCF data may therefore lead to a spurious association between weight gain spurious association between weight gain and clinical response. Why weight gain and clinical response. Why weight gain and clinical response may be associated and clinical response may be associated only in the early weeks of treatment is only in the early weeks of treatment is not clear. This may in part be due to not clear. This may in part be due to individual pharmacokinetic parameters: individual pharmacokinetic parameters: people whose absorption and metabolism people whose absorption and metabolism of antipsychotics resulted in relatively highof antipsychotics resulted in relatively higher plasma drug concentrations very early in er plasma drug concentrations very early in the study might be expected to have greater the study might be expected to have greater symptom improvement and possibly higher symptom improvement and possibly higher weight gain, whereas those with lower plasweight gain, whereas those with lower plasma drug concentrations in the early weeks ma drug concentrations in the early weeks may have neither. A small correlation could may have neither. A small correlation could thus be generated early in treatment and be thus be generated early in treatment and be expected to disappear once doses have been expected to disappear once doses have been adjusted to provide therapeutic drug conadjusted to provide therapeutic drug concentrations for all participants. However, centrations for all participants. However, this presumes a relationship between this presumes a relationship between weight gain and drug dose/concentrations weight gain and drug dose/concentrations that has not yet been established. It is possthat has not yet been established. It is possible that other mechanisms may account for ible that other mechanisms may account for the small and transient association between the small and transient association between weight gain and clinical response. weight gain and clinical response.
Weight gain and study adherence Weight gain and study adherence
The weight gain associated with antiThe weight gain associated with antipsychotic medications, particularly some psychotic medications, particularly some atypical antipsychotics, is of concern atypical antipsychotics, is of concern both because of the potential health both because of the potential health consequences associated with weight gain consequences associated with weight gain and because weight gain may affect the and because weight gain may affect the The weight gain associated with the extended treatment of a first episode of psychosis with either olanzapine or haloperidol is greater than has been previously psychosis with either olanzapine or haloperidol is greater than has been previously estimated. estimated.
& & Olanzapine leads to a significantly greater average weight gain than haloperidol.
Olanzapine leads to a significantly greater average weight gain than haloperidol.
& & Clinical features were not predictive of weight gain with either drug, suggesting Clinical features were not predictive of weight gain with either drug, suggesting that all patients receiving these medications for a first episode of psychosis are at high that all patients receiving these medications for a first episode of psychosis are at high risk of significant weight gain.The degree of clinical improvement experienced with risk of significant weight gain.The degree of clinical improvement experienced with extended treatment does not appear to be meaningfully associated with the amount extended treatment does not appear to be meaningfully associated with the amount of weight gained. of weight gained. The patient sample involved individuals experiencing a first episode of psychosis who were willing to participate in a randomised double-blind clinical trial.The results who were willing to participate in a randomised double-blind clinical trial.The results may not be generalisable to other groups with psychotic disorders or those receiving may not be generalisable to other groups with psychotic disorders or those receiving antipsychotic medication for other illnesses. antipsychotic medication for other illnesses. long-term adherence to these medications. long-term adherence to these medications. In this clinical trial, olanzapine-treated parIn this clinical trial, olanzapine-treated participants were significantly more likely to ticipants were significantly more likely to complete the 2-year trial despite their complete the 2-year trial despite their higher mean weight gain; haloperidolhigher mean weight gain; haloperidoltreated participants were significantly more treated participants were significantly more likely to withdraw because of adverse likely to withdraw because of adverse events and lack of efficacy (Lieberman events and lack of efficacy (Lieberman et et al al, 2003) . Furthermore, BMI increases , 2003) . Furthermore, BMI increases were associated with higher study retention were associated with higher study retention during the first 12 weeks of treatment for during the first 12 weeks of treatment for both treatment groups. Our data do not both treatment groups. Our data do not support the view that weight gain contrisupport the view that weight gain contributes to non-adherence in the short term. butes to non-adherence in the short term. Rather, they suggest that for younger peoRather, they suggest that for younger people with first-episode psychosis the degree ple with first-episode psychosis the degree of clinical improvement may be the best of clinical improvement may be the best predictor of adherence to medication in predictor of adherence to medication in the short term regardless of adverse events, the short term regardless of adverse events, including weight gain. After controlling for including weight gain. After controlling for the effect of clinical improvement, BMI inthe effect of clinical improvement, BMI increase (but not treatment group) remained crease (but not treatment group) remained a significant predictor of study retention. a significant predictor of study retention. Although it is not known what features of Although it is not known what features of olanzapine explain the higher study retenolanzapine explain the higher study retention associated with this treatment, it may tion associated with this treatment, it may be that this is mediated through a mechanbe that this is mediated through a mechanism that also contributes to weight gain. ism that also contributes to weight gain.
In summary, we have demonstrated In summary, we have demonstrated that the weight gain associated with that the weight gain associated with extended treatment of a first-episode psyextended treatment of a first-episode psychosis with either olanzapine or haloperidol chosis with either olanzapine or haloperidol is greater than has been previously estiis greater than has been previously estimated. Our results highlight the importance mated. Our results highlight the importance of evaluating weight gain in clinical trials of evaluating weight gain in clinical trials using data derived from observed cases using data derived from observed cases in addition to LOCF procedures. The in addition to LOCF procedures. The observed weight gain was significantly observed weight gain was significantly greater for olanzapine-treated participants, greater for olanzapine-treated participants, but no other clinical factors were predictive but no other clinical factors were predictive of the amount of weight gained. Our results of the amount of weight gained. Our results suggest that weight gain is associated with suggest that weight gain is associated with clinical improvement but in a minor and clinical improvement but in a minor and transient way, which is unlikely to be of transient way, which is unlikely to be of clinical significance. Nor is it clear whether clinical significance. Nor is it clear whether weight gain adversely affects short-term weight gain adversely affects short-term treatment adherence. However, it is clear treatment adherence. However, it is clear that the extent of weight gain observed that the extent of weight gain observed justifies additional study of the potential justifies additional study of the potential health consequences that may be experihealth consequences that may be experienced by young people who are being enced by young people who are being treated for a first-episode of psychosis. treated for a first-episode of psychosis.
